Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Dec 22, 2025
Health Canada approves Clinical Trial Application for Koala
Dec 15, 2025
FDA approves DAYBUE STIX (trofinetide), powder formulation
Dec 09, 2025
One-month administrative delay to FDA meeting for HIE
Nov 24, 2025
Application for quotation of securities - NEU
Nov 10, 2025
Investor Presentation, 10 November 2025
Nov 06, 2025
Record DAYBUE net sales of US$101.1 million in Q3 2025
Oct 20, 2025
Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
Oct 17, 2025
Change of registered office in Australia
Oct 03, 2025
Application for quotation of securities - NEU
Sep 22, 2025
Notification regarding unquoted securities - NEU
1
2
3
4
5
6
7
8
9
10
11
12
13
Next
